Checkpoint Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc. is a U.S.-based biopharmaceutical company that was listed on the NASDAQ in the United States (United States) and historically focused on precision oncology and immunotherapy. Founded in 2014, the company began principal operations in March 2015 and is headquartered in Waltham, Massachusetts. Checkpoint was originally built as a development-stage platform aimed at advancing novel therapies for solid tumor cancers, with Fortress Biotech as a controlling stakeholder. For most of its history, the company’s value creation model was centered on clinical development, regulatory preparation, and eventual commercialization rather than on a broad, established commercial franchise. The company’s defining recent milestone has been cosibelimab, marketed as UNLOXCYT. This is a PD-L1 blocking antibody approved for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or curative radiation. Checkpoint has described UNLOXCYT as the first and only FDA-approved anti-PD-L1 treatment for this indication. That approval was strategically important because it shifted Checkpoint from a pure clinical-stage story to an emerging commercial oncology company with a differentiated asset in a niche but clinically meaningful segment. From a competitive standpoint, Checkpoint has remained a small-cap biotech relative to large pharmaceutical groups and better-capitalized oncology peers. Its positioning is differentiated by a focused indication in skin cancer, where physician awareness, reimbursement, and commercial execution matter materially. The company’s main business lines have centered on the acquisition, development, and commercialization of novel treatments for solid tumor cancers. Unlike diversified pharma companies, Checkpoint has depended heavily on a narrow asset base, which makes UNLOXCYT adoption, regulatory expansion, and execution in commercialization critical to its long-term profile. Geographically, Checkpoint is primarily a U.S. company, with commercial and regulatory activity centered on the domestic market, while historically maintaining interest in selected non-U.S. development opportunities. The company also relied on international partners and contract manufacturers for development and supply chain execution. In terms of recent major events, the most important development was the announced merger agreement with Sun Pharmaceutical Industries in March 2025, followed by the completion of the acquisition on May 30, 2025. As a result, Checkpoint ceased to be an independent NASDAQ-listed equity story, but its operating history remains relevant for investors assessing oncology commercialization risk, the strategic value of UNLOXCYT, and the company’s role in recent M&A activity.